5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The purpose of this study was to evaluate the enhancement value of chloroquine analogs when used in combination with Akt inhibitors on the MDA-MB468, MDA-MB231 and MCF7 human breast cancer cell lines. The result showed that the combination of certain chloroquine analogs and Akt inhibitors are highly effective. In particular, the chloroquine analog N′-(7-fluoro-quinolin-4-yl)- N, N-dimethyl-ethane-1,2-diamine (compound 5) was highly effective in sensitizing cancer cell killing when combined with either Akt inhibitor 8 (1-{1-[4-(7-phenyl-1H-imidazo[4,5- g]quinoxalin-6-yl)-benzyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one) or 9 ([4-(2-chloro-4 a,10 a-dihydro-phenoxazin-10-yl)-butyl]-diethyl-amine hydrochloride). Importantly, the enhancement of chloroquine analogs 5 on cell killing by Akt inhibitors 8 and 9 was cancer-specific. Thus, this combinational approach is highly promising in controlling tumors with a minimum side effect. Structural analysis of effective and ineffective chloroquine analogs suggests that the 4-aminoquinoline scaffold and lateral side chain of dimethylamino functionality play an important role for the enhancement of cell killing by Akt inhibitors.

          Graphical abstract

          In the present study, the combinational effects of chloroquine analogs and Akt inhibitors were evaluated for their cell killing activity on cancer and non-cancer breast cells

          .

          Related collections

          Author and article information

          Contributors
          Journal
          Eur J Med Chem
          Eur J Med Chem
          European Journal of Medicinal Chemistry
          Elsevier Masson SAS.
          0223-5234
          1768-3254
          11 November 2009
          February 2010
          11 November 2009
          : 45
          : 2
          : 705-709
          Affiliations
          [a ]Tumour Biology, Northeastern Ontario Regional Cancer Program at the Sudbury Regional Hospital, 41 Ramsey Lake Road, Sudbury, Ontario P3E 5J1, Canada
          [b ]Department of Biology, Laurentian University, Sudbury, Ontario P3E 2C6, Canada
          [c ]Oncology, Northeastern Ontario Regional Cancer Program at the Sudbury Regional Hospital, 41 Ramsey Lake Road, Sudbury, Ontario P3E 5J1, Canada
          [d ]Department of Medical Sciences, The Northern Ontario School of Medicine, 935 Ramsey Lake Road, Sudbury, Ontario P3E 2C6, Canada
          Author notes
          []Corresponding author. Tumour Biology, Northeastern Ontario Regional Cancer Program at the Sudbury Regional Hospital, 41 Ramsey Lake Road, Sudbury, Ontario P3E 5J1, Canada. Tel.: +1 705 5226237x2703; fax: +1 705 5237326. hlee@ 123456hrsrh.on.ca
          Article
          S0223-5234(09)00587-X
          10.1016/j.ejmech.2009.11.017
          7115421
          19945197
          40a3cb0a-4e6a-43df-bfae-a1f84ae83aab
          Copyright © 2009 Elsevier Masson SAS. All rights reserved.

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 21 July 2009
          : 28 October 2009
          : 5 November 2009
          Categories
          Article

          Pharmacology & Pharmaceutical medicine
          chloroquine analog,akt inhibitor,breast cancer,chemotherapeutics,184b5

          Comments

          Comment on this article